Novavax reported $238.03M in Cash and Equivalent for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Adamas Pharmaceuticals ADMS:US 88.8M 36.03M
Adma Biologics ADMA:US $ 42.41M 19.56M
Agenus AGEN:US $ 73.54M 45.82M
AstraZeneca AZN:LN 15567M 7931M
Astrazeneca AZN:US $ 15567M 7931M
Biocryst Pharmaceuticals BCRX:US $ 218.43M 8.47M
BioSpecifics Technologies BSTC:US 2.87M 14M
Dynavax Technologies DVAX:US $ 129.61M 50.55M
Genocea Biosciences GNCA:US $ 60.4M 5.64M
Geron GERN:US $ 57.64M 26.11M
GlaxoSmithKline GSK:LN 3503M 1254M
Kindred Biosciences KIN:US $ 46.72M 33.8M
Mannkind MNKD:US $ 62.52M 185.31M
Minerva Neurosciences NERV:US $ 74.22M 5.92M
Moderna Inc MRNA:US 5.6B 161M
Novartis NVS:US $ 5117M 1316M
Novavax NVAX:US $ 238.03M 4.68M
Pain Therapeutics PTIE:US $ 278.25M 3.94M
Peregrine Pharmaceuticals PPHM:US $ 159.69M 10.22M
Sarepta Therapeutics SRPT:US $ 1697.28M 215.44M
Tg Therapeutics TGTX:US $ 456.22M 15.3M